Gene: SHANK3

85358
DEL22q13.3|PROSAP2|PSAP2|SCZD15|SPANK-2
SH3 and multiple ankyrin repeat domains 3
protein-coding
22q13.33
Ensembl:ENSG00000251322 MIM:606230 UniprotKB:Q9BYB0
NG_008607.2
PubMed
0   ANCO-SNPs
AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.354e-1 (AD)  5.607e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg04865531chr22:51159147SHANK3Gene body3.175e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CBX60.922
DDN0.92
MAP3K100.914
CRTC10.91
FBXL160.91
DENND4B0.906
CAMK2A0.905
PPP1R9B0.902
ZMIZ20.902
FBXO410.901

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.616
OR4F29-0.58
RBP7-0.403
MYOT-0.402
UTS2-0.401
C9orf135-0.397
CRNDE-0.396
ANXA13-0.395
ODAM-0.392
SNHG18-0.39

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0112692,5-hexanedione"[carbendazim co-treated with 2,5-hexanedione] affects the expression of SHANK3 mRNA"22382377
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of SHANK3 mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHANK3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHANK3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHANK3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHANK3 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SHANK3 mRNA27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of SHANK3 mRNA24449571
D001151ArsenicArsenic affects the methylation of SHANK3 gene25304211
D001280AtrazineAtrazine results in decreased expression of SHANK3 mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SHANK3 mRNA21839799
C006780bisphenol A[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SHANK3 promoter23359474
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of SHANK3 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of SHANK3 gene28505145
D019328Buthionine SulfoximineButhionine Sulfoximine results in decreased expression of SHANK3 mRNA15878706
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA25607892
C006698carbendazim"[carbendazim co-treated with 2,5-hexanedione] affects the expression of SHANK3 mRNA"22382377
C004656chloroacetaldehydechloroacetaldehyde affects the expression of SHANK3 mRNA25596134
C059262cidofovircidofovir affects the expression of SHANK3 mRNA25596134
D004002Clodronic AcidClodronic Acid results in decreased expression of SHANK3 mRNA25596134
C018021cobaltous chloridecobaltous chloride results in decreased expression of SHANK3 mRNA24386269
D003042Cocaine[Cocaine co-treated with FOS protein mutant form] results in decreased expression of SHANK3 mRNA18355967
D003300CopperCopper results in decreased expression of SHANK3 protein25007851
D003300CopperCopper inhibits the reaction [Potassium results in increased expression of SHANK3 protein]25007851
D003300CopperCopper inhibits the reaction [zinc chloride results in increased expression of SHANK3 protein]25007851
C029892cupric chloride[COMMD1 protein co-treated with zinc chloride co-treated with cupric chloride] results in increased expression of SHANK3 protein25007851
D016572CyclosporineCyclosporine results in decreased expression of SHANK3 mRNA25562108
C014347decitabinedecitabine results in increased expression of SHANK3 mRNA17419801
D003993Dibutyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SHANK3 promoter23359474
C000944dicrotophosdicrotophos results in increased expression of SHANK3 mRNA28302478
D004041Dietary FatsDietary Fats results in increased expression of SHANK3 mRNA25016146
D004051Diethylhexyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SHANK3 promoter23359474
D004317DoxorubicinDoxorubicin affects the methylation of SHANK3 gene28962528
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA25607892
D000431EthanolEthanol results in decreased expression of SHANK3 mRNA29018328
C069837fullerene C60fullerene C60 results in increased expression of SHANK3 mRNA19167457
C039281furanfuran results in decreased expression of SHANK3 mRNA25539665|2619464
D017313FenretinideFenretinide results in increased expression of SHANK3 mRNA28973697
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of SHANK3 mRNA26254443
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of SHANK3 mRNA"24972896
D008070Lipopolysaccharides[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of SHANK3 mRNA16415329
D008715MethionineMethionine results in decreased expression of SHANK3 mRNA17419801
D008715MethionineMethionine results in decreased expression of SHANK3 protein17419801
D008731MethoxychlorMethoxychlor results in increased methylation of SHANK3 gene23303685
D008746Methylazoxymethanol AcetateMethylazoxymethanol Acetate results in decreased expression of SHANK3 mRNA28349193
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of SHANK3 mRNA24810058
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of SHANK3 mRNA25607892
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of SHANK3 mRNA"21673326
C009618O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate"PON1 protein affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of SHANK3 mRNA]"21673326
D009966OrphenadrineOrphenadrine affects the expression of SHANK3 mRNA23665939
D010100OxygenOxygen deficiency results in increased expression of SHANK3 mRNA25596134
D052638Particulate MatterParticulate Matter results in decreased expression of SHANK3 mRNA29121345
D052638Particulate MatterParticulate Matter results in decreased expression of SHANK3 protein29121345
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHANK3 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of SHANK3 mRNA26272509
D010705PhosgenePhosgene affects the expression of SHANK3 mRNA16300373
D010936Plant ExtractsPlant Extracts results in decreased expression of SHANK3 mRNA23557933
D011188PotassiumCopper inhibits the reaction [Potassium results in increased expression of SHANK3 protein]25007851
D011188PotassiumPotassium results in increased expression of SHANK3 protein25007851
D011192Potassium DichromatePotassium Dichromate results in decreased expression of SHANK3 mRNA23608068
D011441PropylthiouracilPropylthiouracil results in decreased expression of SHANK3 mRNA24780913
D011899Ranitidine[Lipopolysaccharides co-treated with Ranitidine] results in decreased expression of SHANK3 mRNA16415329
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHANK3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SHANK3 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of SHANK3 mRNA23179753|2627250
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of SHANK3 gene25560391
C111237vorinostatvorinostat results in decreased expression of SHANK3 mRNA27188386
D015032ZincZinc affects the folding of SHANK3 protein16793273
D015032ZincZinc binds to SHANK3 protein16793273
C016837zinc chloride[COMMD1 protein co-treated with zinc chloride co-treated with cupric chloride] results in increased expression of SHANK3 protein25007851
C016837zinc chlorideCopper inhibits the reaction [zinc chloride results in increased expression of SHANK3 protein]25007851
C016837zinc chloridezinc chloride results in increased expression of SHANK3 protein25007851

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003779actin binding-IEA-  
GO:0005515protein binding-IPI17474147  21988832  
GO:0008022protein C-terminus binding-ISS-  
GO:0008270zinc ion binding-ISS-  
GO:0017124SH3 domain binding-ISS-  
GO:0030159receptor signaling complex scaffold activity-IBA21873635  
GO:0030160GKAP/Homer scaffold activity-IBA21873635  
GO:0030160GKAP/Homer scaffold activity-ISS-  
GO:0035255ionotropic glutamate receptor binding-IBA21873635  
GO:0035255ionotropic glutamate receptor binding-ISS-  
GO:0043621protein self-association-ISS-  
GO:0097110scaffold protein binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-ISS-  
GO:0007411axon guidance-TAS-  
GO:0007416synapse assembly-IBA21873635  
GO:0007416synapse assembly-ISS-  
GO:0007612learning-IMP17173049  21378602  
GO:0007612learning-ISS-  
GO:0007613memory-ISS-  
GO:0021773striatal medium spiny neuron differentiation-ISS-  
GO:0030534adult behavior-IMP17173049  21378602  
GO:0032232negative regulation of actin filament bundle assembly-ISS-  
GO:0035176social behavior-IMP17173049  21378602  
GO:0035176social behavior-ISS-  
GO:0042297vocal learning-IMP17173049  21378602  
GO:0045794negative regulation of cell volume-ISS-  
GO:0048170positive regulation of long-term neuronal synaptic plasticity-ISS-  
GO:0048854brain morphogenesis-IBA21873635  
GO:0048854brain morphogenesis-ISS-  
GO:0051124synaptic growth at neuromuscular junction-IBA21873635  
GO:0051705multi-organism behavior-IBA21873635  
GO:0051835positive regulation of synapse structural plasticity-ISS-  
GO:0051968positive regulation of synaptic transmission, glutamatergic-IBA21873635  
GO:0051968positive regulation of synaptic transmission, glutamatergic-ISS21795692  
GO:0060291long-term synaptic potentiation-IBA21873635  
GO:0060997dendritic spine morphogenesis-IBA21873635  
GO:0060997dendritic spine morphogenesis-ISS-  
GO:0060999positive regulation of dendritic spine development-IBA21873635  
GO:0060999positive regulation of dendritic spine development-ISS21795692  
GO:0061001regulation of dendritic spine morphogenesis-ISS21795692  
GO:0071625vocalization behavior-IMP17173049  21378602  
GO:0071625vocalization behavior-ISS21167025  
GO:0097107postsynaptic density assembly-IBA21873635  
GO:0097107postsynaptic density assembly-ISS-  
GO:0097113AMPA glutamate receptor clustering-ISS21795692  
GO:0097114NMDA glutamate receptor clustering-ISS-  
GO:0097117guanylate kinase-associated protein clustering-ISS-  
GO:1900271regulation of long-term synaptic potentiation-ISS-  
GO:1900273positive regulation of long-term synaptic potentiation-ISS-  
GO:1900451positive regulation of glutamate receptor signaling pathway-ISS21795692  
GO:1900452regulation of long term synaptic depression-ISS21795692  
GO:2000311regulation of AMPA receptor activity-IBA21873635  
GO:2000463positive regulation of excitatory postsynaptic potential-IBA21873635  
GO:2000463positive regulation of excitatory postsynaptic potential-ISS21795692  
GO:2000969positive regulation of AMPA receptor activity-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005829cytosol-TAS-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membraneCOLOCALIZES_WITHIBA21873635  
GO:0005886plasma membrane-ISS-  
GO:0008328ionotropic glutamate receptor complexCOLOCALIZES_WITHIBA21873635  
GO:0014069postsynaptic density-IBA21873635  
GO:0014069postsynaptic density-ISS-  
GO:0030054cell junction-IEA-  
GO:0030425dendrite-IBA21873635  
GO:0043005neuron projection-IBA21873635  
GO:0043005neuron projection-ISS-  
GO:0043197dendritic spine-IBA21873635  
GO:0043197dendritic spine-IEA-  
GO:0044309neuron spine-IBA21873635  
GO:0044309neuron spine-ISS-  
GO:0045211postsynaptic membraneCOLOCALIZES_WITHIBA21873635  
GO:0045211postsynaptic membrane-IEA-  
GO:0060170ciliary membrane-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemIEA
R-HSA-112316Neuronal SystemTAS
R-HSA-1266738Developmental BiologyTAS
R-HSA-422475Axon guidanceTAS
R-HSA-6794361Neurexins and neuroliginsIEA
R-HSA-6794361Neurexins and neuroliginsTAS
R-HSA-6794362Protein-protein interactions at synapsesIEA
R-HSA-6794362Protein-protein interactions at synapsesTAS
R-HSA-8853659RET signalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29032150Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases. (2018 Jan 30)Sundararajan TGene